Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer

Simple item page
dc.contributor.authorKuroda, Yuuki
dc.contributor.authorMurakami, Naoya
dc.contributor.authorMorota, Madoka
dc.contributor.authorSekii, Shuhei
dc.contributor.authorTakahashi, Kana
dc.contributor.authorInaba, Koji
dc.contributor.authorMayahara, Hiroshi
dc.contributor.authorIto, Yoshinori
dc.contributor.authorYoshimura, Ryo-ichi
dc.contributor.authorSumi, Minako
dc.contributor.authorKagami, Yoshikazu
dc.contributor.authorKatsumata, Noriyuki
dc.contributor.authorKasamatsu, Takahiro
dc.contributor.authorItami, Jun
dc.date.accessioned2023-01-10T15:58:24Z
dc.date.available2023-01-10T15:58:24Z
dc.date.issued2012-06-15
dc.description.abstractThe purpose of this retrospective study is to investigate the impact of concurrent chemotherapy on definitive radiotherapy for the International Federation of Gynecology and Obstetrics (FIGO) IIIb cervical cancer. Between 2000 and 2009, 131 women with FIGO IIIb cervical cancer were treated by definitive radiotherapy (i.e. whole pelvic external beam radiotherapy for 40–60 Gy in 20–30 fractions with or without center shielding and concomitant high-dose rate intracavitary brachytherapy with 192-iridium remote after loading system for 6 Gy to point A of the Manchester method). The concurrent chemotherapy regimen was cisplatin (40 mg/m2/week). After a median follow-up period of 44.0 months (range 4.2–114.9 months) and 62.1 months for live patients, the five-year overall survival (OS), loco-regional control (LRC) and distant metastasis-free survival (DMFS) rates were 52.4, 80.1 and 59.9%, respectively. Univariate and multivariate analyses revealed that lack of concurrent chemotherapy was the most significant factor leading to poor prognosis for OS (HR = 2.53; 95% CI 1.44–4.47; P = 0.001) and DMFS (HR = 2.53; 95% CI 1.39–4.61; P = 0.002), but not for LRC (HR = 1.57; 95% CI 0.64–3.88; P = 0.322). The cumulative incidence rates of late rectal complications after definitive radiotherapy were not significantly different with or without concurrent chemotherapy (any grade at five years 23.9 vs 21.7%; P = 0.669). In conclusion, concurrent chemotherapy is valuable in definitive radiotherapy for Japanese women with FIGO IIIb cervical cancer.en_US
dc.identifier.citationKuroda, Y., Murakami, N., Morota, M., Sekii, S., Takahashi, K., Inaba, K., Mayahara, H., Ito, Y., Yoshimura, R., Sumi, M., Kagami, Y., Katsumata, N., Kasamatsu, T., & Itami, J. (2012). Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. Journal of radiation research, 53(4), 588–593. https://doi.org/10.1093/jrr/rrs010en_US
dc.identifier.otherDOI: 10.1093/jrr/rrs010
dc.identifier.urihttps://hdl.handle.net/20.500.14041/5354
dc.language.isoen_USen_US
dc.publisherJournal of Radiation Researchen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectCervical Canceren_US
dc.subjectIIIben_US
dc.subjectChemotherapyen_US
dc.subjectRadiotherapyen_US
dc.subjectHDRen_US
dc.titleImpact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical canceren_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
rrs010.pdf
Size:
141.19 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.65 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
SRHR Evidence (Best practice, Systematic reviews)